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Abstract
Oestrogen receptor (ER) is expressed in approximately 60%-70% of human breast
cancer. Clinical trials and retrospective analyses have shown that ER-positive (ER+)
tumours are more tolerant to chemotherapeutic drug resistance than ER-negative
(ER) tumours. In addition, isobavachalcone (IBC) is known as a kind of phytoestro-
gen with antitumour effect. However, the underlying mechanism of IBC in ER+
breast cancer needs to be elucidated further. Our in vitro experiments showed that
IBC could attenuate 17b-estradiol (E2)-induced paclitaxel resistance and that E2
could stimulate CD44 expression in ER+ breast cancer cells but not in ER cells.
Meanwhile, E2 could promote ERa expression to render ER+ breast cancer cells
resistant to paclitaxel. Furthermore, we established paclitaxel-resistant breast cancer
cell lines and determined the function of ERa in the enhancement of paclitaxel resis-
tance via the regulation of CD44 transcription. IBC down-regulated ERa and CD44
expression and thus inhibited tumour growth in paclitaxel-resistant xenograft mod-
els. Overall, our data demonstrated for the first time that IBC could decrease CD44
expression level via the ERa pathway and make ER+ breast cancer cells sensitive to
paclitaxel treatment.
K E YWORD S
breast cancer, CD44, isobavachalcone, oestrogen receptor alpha, paclitaxel resistance
1 | INTRODUCTION
Breast cancer is one of the most common malignant tumours in
women, with high rate of morbidity and metastasis.1 Oestrogen
receptor alpha (ERa) is positive in approximately 60%-70% of breast
cancer patients.2,3 Cumulative data show that ERa+ breast cancer
cells are more resistant to paclitaxel, a first-line chemotherapeutic
drug for breast cancer, than are ER- breast cancer.4,5 Therefore,
chemotherapy failure caused by paclitaxel resistance is considered a
substantial obstacle in the treatment of ER+ breast cancer.6,7
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However, the underlying mechanism of chemotherapeutic drug resis-
tance in ER+ breast cancer has not yet been elucidated.
17b-Estradiol (E2) can regulate and maintain a series of physio-
logical processes, such as reproduction, CNS development and meta-
bolic balance.8 Many cellular responses to E2 are mediated by
oestrogen receptors (ERs), including ERa and ERb. Although clinical
and experimental data have confirmed the key role of ERa in breast
cancer, the role of ERb in breast cancer remains controversial.8,9
Recent studies have demonstrated that expression of ERa can pre-
vent paclitaxel-induced apoptosis in breast cancer MCF-7 cells.10,11
ERa can act as a nuclear receptor and regulate target gene transcrip-
tion via the “classical” model or the “nonclassical” model.12 In addi-
tion to its role in the “classical” model of gene regulation through
oestrogen response elements (EREs) in promoter regions, ERa can
form protein complexes with other transcription factors, such as
Sp1, Ap1 and NF-jB, to regulate gene transcription involved in the
“nonclassical” model.12-14 These observations suggest that ERa can
regulate a large variety of genes that are associated with the devel-
opment of chemotherapy resistance in ER+ breast cancer cells.
Psoralen, a traditional Chinese herb, is isolated from dried ripe
fruits of leguminous Psoralea corylifolia L.15-17 It is warm natured and
pungent flavoured, with the effect of enriching the kidney and
strengthening yang.18 Recent studies have shown that psoralen has
some biological functions, such as blood vessel dilatation, myocardial
contractility enhancement and antifungal, anticancer and oestrogen-
like effects.19 Modern pharmacological studies have also shown that
isobavachalcone (IBC), an important component of psoralen, has
strong antibacterial, antioxidant, anti-reverse transcriptase, antituber-
cular and anticancer abilities.20,21 Previous studies have reported
that IBC inhibits tumour formation in mouse skin cancer and induces
apoptosis in neuroblastoma.22,23 However, the potential functions of
IBC in cancer-related treatment need further study.
CD44 and CD24 are characteristic of the cancer stem cell phe-
notype, and these molecules are closely associated with poor prog-
nosis and chemotherapy resistance in cancer.24-27 Recently, natural
substances from plants have been documented as effective interven-
tion agents in the down-regulation of CD44/CD24 expression in
experimental breast carcinoma.28 However, whether IBC can directly
regulate CD44/CD24 expression to decrease paclitaxel resistance in
ER+ breast cancer cells remains unclear. This study aimed to explore
whether IBC influences resistance of breast cancer cells to paclitaxel
by regulating CD44/CD24 expression. In this study, first, we aimed
to establish a close correlation between CD44 and ERa expression
in ER+ breast cancer cells with oestrogen stimulation or the develop-
ment of paclitaxel resistance. Second, we explored the function of
ERa in the enhancement of paclitaxel resistance via the regulation of
CD44 expression. Finally, we determined that IBC could enhance the
sensitivity of paclitaxel-resistant breast cancer cells and reduce the
growth of xenograft tumours via the regulation of CD44 expression.
Taken together, for the first time, our results demonstrated that inhi-
bition of ERa by IBC can down-regulate CD44 expression and thus
decrease paclitaxel resistance in ER+ breast cancer cells and xeno-
graft tumour models.
2 | MATERIALS AND METHODS
2.1 | Cell culture and chemicals
The human breast cancer cell lines ZR-75-1, MCF-7 and MDA-
MB-231 were obtained from the ATCC. ZR-75-1 cells and ZR-75-
1/R cells were cultured in DMEM; MCF-7 cells and MCF-7/R cells
were cultured in EMEM; and MDA-MB-231 cells were cultured in
L-15 medium. All culture media, containing 10% (v/v) foetal
bovine serum, penicillin (200 U/mL) and streptomycin (100 lg/
mL), were purchased from Gibco Life Technology (Grand Island,
NY, USA). Paclitaxel (Taxol), E2, IBC and 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide (MTT) were obtained from
Sigma (St. Louis, MO, USA). Antibodies against ERa and P-gp were
purchased from Abcam (Cambridge, MA, USA). The anti-CD44
antibody was purchased from Proteintech (Proteintech Group,
Chicago, IL, USA).
2.2 | Stepwise selection of cells
We simulated the development of resistance in clinics by weekly
treating ZR-75-1 and MCF-7 cells with paclitaxel to generate pacli-
taxel-resistant cell lines. ZR-75-1 and MCF-7 cells were treated in a
stepwise manner with increasing concentrations of paclitaxel (begin-
ning concentration at 2.5 nmol/L and final concentration at
50 nmol/L) to generate ZR-75-1/R and MCF-7/R cells after
8 months. The resistance index (RI) of cell variants represents the
IC50 value of paclitaxel-resistant ZR-75-1/R and MCF-7/R cells
divided by the IC50 value of the parental ZR-75-1 and MCF-7 cells
for each dose of paclitaxel tested.
2.3 | Cell viability assay
ZR-75-1 and MCF-7 cells were seeded at 5000 cells per well in 96-
well plates and then treated with the indicated concentrations of
paclitaxel (72 hours) or E2/IBC (48 hours). Subsequently, the cells
were treated with 10 lL MTT (5 mg/mL) at 37°C for 4 hours fol-
lowed by 150 lL dimethyl sulphoxide, and cell viability was deter-
mined by measuring the absorbance at 570 nm using a microplate
reader (Bio-Rad, California, USA).
2.4 | RNA isolation and real-time PCR
Total RNA was isolated using TRIzol reagent (Invitrogen) according
to the manufacturer’s instructions. Approximately 1 lg of extracted
RNA was reverse transcribed to cDNA using random primers. Real-
time PCR was performed with cDNA using SYBR green (TOYOBO).
The primers used were as follows: CD44 (forward 50-CGCTATGTC
CAGAAAGGAGAAT-30 and reverse 50-CTGCTCACGTCATCATCAG
TAG-30); CD24 (forward 50-TCAAGTAACTCCTCCCAGAGTA-30
and reverse 50-AGAGAGTGAGACCACGAAGA-30); and GAPDH
(forward 50-CAGGGCTGCTTTTAACTCTGGTAA-30 and reverse
50-GGGTGGAATCATATTGGAACATGT-30).
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2.5 | Transient transfection
Cells were seeded and transfected with LipofectamineTM 2000 (Invit-
rogen, Shanghai, China) according to the manufacturer’s protocol.
ZR-75-1, MCF-7, ZR-75-1/R and MCF-7/R cells were plated in
six-well plates at a density of 1 9 106 cells/well. The cells were trans-
fected with pcDNA3.1-ERa (ERa expression vector), pRNAT-H1.1-ERa-
shRNA (ERa-shRNA) and si-CD44 (CD44-targeting siRNA) plasmids
using LipofectamineTM 2000. ERa-targeted shRNA was constructed
and described in our previously work.29 The siRNA used for silencing
CD44 gene was purchased from GenePharma (Shanghai, China). The
sequences for siCD44-1 and siCD44-2 were as follows: sense 50
GGACCAAUUACCAUAACUATT 30, antisense 50 UAGUUAUGGUA
AUUGGUCCTT 30 and sense 50 GCAGUCAACAGUCGAAGAATT 30 ,
antisense 50 UUCUUCGACUGUUGACUGCTT 30. As a negative control,
pcDNA3.1, pGC-control-shRNA and si-control were used.
2.6 | Western blotting
Total protein was extracted from cultured cells, subjected to 8%-
12% SDS-polyacrylamide gel electrophoresis and transferred onto
0.45-lm PVDF membranes (Millipore). The membranes were then
blocked with 5% milk-TBST for 1 hour and incubated with primary
antibodies against CD44 (diluted 1:1000), ERa (diluted 1:1000), P-gp
(diluted 1:1000) and b-actin (diluted 1:5000 in TBST) overnight.
After incubation with appropriate secondary antibodies for 1 hour at
room temperature, the membranes were detected by Tanon 5200
Imaging System (Shanghai, China).
2.7 | Clonogenic cell survival assay
Cells suspended in fresh culture medium were plated at a density of
400 cells/well onto 6-cm plates and incubated for 24 hours and then
cultured in fresh medium containing 5 nmol/L paclitaxel. At the end
of 2 weeks of incubation, the cells were fixed with cold methanol and
stained with crystal violet (Beyotime, China) for 20 minutes at room
temperature. Thereafter, the plates were gently washed with water
and allowed to air-dry. All experiments were performed in triplicate.
2.8 | Flow cytometry assay
Approximately 106 cultured cells were harvested and fixed in 75%
ethanol diluted in PBS at 20°C overnight. The cells were then incu-
bated in PBS containing 100 lg/mL propidium iodide (PI), 100 lg/
mL RNase and 0.1% Triton X-100 at room temperature for 30 min-
utes before flow cytometry analysis. Cell cycle distribution and DNA
content were determined using a BD FACSCalibur system (Becton,
Dickinson and Company, USA).
2.9 | Tumour xenograft and immunohistochemistry
assay
Animal experiments were approved by the Animal Care Committee
of Nanjing First Hospital, Nanjing Medical University (Approval No.
SYXK20160006). Approximately 5 9 106 MCF-7/R cells were
injected into the mammary fat pads of 5-week-old female athymic
nude mice. The mice were randomly assigned into two groups of six.
When the size of the xenograft reached approximately 50 mm3, IBC
was intraperitoneally administered daily at 100 mg/kg into the nude
mice. Tumour volumes were calculated at the indicated time-points
with the formula: p/6 9 length 9 width2. Tumour samples from the
mice were deparaffinized and rehydrated. After blocking the endoge-
nous peroxidase activity, the sections incubated with primary mono-
clonal anti-ERa and anti-CD44 antibodies at a dilution of 1:500
overnight at 4°C. The sections were incubated with appropriate
HRP-conjugated secondary antibody for 1 hour at room tempera-
ture. Colour was developed with 3-amino-9-ethylcarbazole solution.
Image pro plus (IPP) was used as the method of quantitative
image analysis on immunohistochemical staining, evaluating the
expressing protein of ERa and CD44 gene by IBC treatment. Firstly,
the positive area (ERa or CD44 protein staining) in the image was
taken as AOI (area of interest). Then the value of SA (sum area) and
IOD (integrated optical density) was measured by IPP software, and
the value of MOD (mean optical density) was calculated as the fol-
lowing formula: MOD = IOD/SA.
2.10 | Statistical analysis
Each of the experiments was repeated at least three times. Values
are expressed as the mean  SD of triplicate measurements unless
otherwise noted. Student’s paired t test was used to analyse differ-
ences between the sample of interest and its control. P < .05 was
considered statistically significant.
3 | RESULTS
3.1 | IBC decreased resistance of ER+ breast cancer
to paclitaxel
Although oestrogen can maintain biological functions in breast can-
cer cells, its roles in the stimulation of drug resistance in breast can-
cer cells are still controversial. Therefore, we analysed the viable
number of breast cancer cells after treatment with different concen-
trations of E2. Our data indicated that the number of viable cells dis-
played an increasing tendency in ER+ ZR-75-1 and MCF-7 cells but
not in ER- MDA-MB-231 cells (Figure 1A). After 2 weeks of incuba-
tion with 5 nmol/L paclitaxel, the number of colonies formed by ZR-
75-1 and MCF-7 cells in the E2 group was higher than that in the
control group (Figure 1B), suggesting that E2 could promote the pro-
liferation of ER+ breast cancer cells to make them resistant to pacli-
taxel.
IBC is well-known as a kind of phytoestrogen, but its therapeutic
mechanism in breast cancer remains unclear. To investigate the
effect of IBC on breast cancer cells, we carried out cell viability
assays in the presence of 1 lmol/L E2. Our results demonstrated
that the viability significantly decreased in ZR-75-1 and MCF-7 cells
treated with 8 lmol/L IBC (Figure 1C). In addition, fewer colonies of
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ZR-75-1 and MCF-7 cells were formed in the E2+IBC group than in
the E2 group (Figure 1B). These findings indicated that E2 could
increase the resistance of ER+ breast cancer cells to paclitaxel, while
IBC could attenuate E2-induced paclitaxel resistance.
3.2 | CD44 was up-regulated by E2 in ER+ breast
cancer cells
Although CD44 and CD24 expression is a poor prognostic marker for
different tumours including breast cancer,24,30 the role of CD44 and
CD24 in paclitaxel resistance of breast cancer cells stimulated by E2
needs further study. Therefore, we analysed CD44 and CD24 expres-
sion in breast cancer cells treated with different concentrations of E2
using real-time PCR. Indeed, in comparison with that in ER- MDA-
MB-231 cells (Figure 2C), the expression of CD44 displayed an
increasing tendency with increasing E2 concentration in ER+ ZR-75-1
and MCF-7 cells (Figure 2A and B). In addition, the expression levels
of CD24 mRNA decreased in all breast cancer cells after stimulation
with the same concentration of E2 (Figure 2D, E and F). Western blot-
ting results further demonstrated that the expression levels of the
CD44 protein were specifically elevated in ZR-75-1 and MCF-7 cells
after E2 stimulation (Figure 2G). These results indicated that CD44
plays an important role in ER+ breast cancer cells in the presence of
E2 stimulation. To further identify the function of CD44 during the
response to paclitaxel, we performed siRNA-mediated knockdown of
CD44 in MCF-7 cells (Figure 2H). Colony formation assay showed
that fewer paclitaxel-resistant colonies were formed in the si-CD44
group, which was, than in the control group (Figure 2I). These data
suggested that CD44 expression might be involved in the resistance
to paclitaxel-mediated E2 stimulation.
3.3 | ERa induced by E2 enhanced CD44 expression
in breast cancer cells
Our previous study showed that ERa was essentially involved in
chemoresistance, which may be attributed to its role as a nuclear
transcriptional factor in regulating some important tumour drug-
resistant genes.10 Thus, we detected the expression of ERa in ER+
breast cancer cells stimulated by E2. Western blotting displayed that
E2 could increase ERa expression levels in ZR-75-1 and MCF-7 cells
(Figure 3A), suggesting a significant positive correlation between
ERa and CD44 in ER+ breast cancer cells. To further explore
whether CD44 expression was regulated by ERa, we examined the
expression of CD44 in ZR-75-1 and MCF-7 cells transfected with
ERa. The transfection efficiency of the ERa expression vector was
confirmed by Western blotting (Figure 3B). Additionally, real-time
PCR showed that compared with that in the cells transfected with
control plasmids, the expression of CD44 mRNA was up-regulated in
F IGURE 1 IBC decreased paclitaxel resistance in ER+ breast cancer. A, ZR-75-1 (ER+), MCF-7 (ER+) and MDA-MB-231 (ER) breast cancer
cells were treated with the indicated concentrations of E2 for 72 h and subjected to cell viability assay. B, ER+ and ER breast cancer cells
were treated with E2 (1 lmol/L) for 24 h and subsequently treated with the indicated concentrations of IBC for 72 h. C, ER+ and ER breast
cancer cells were pretreated with E2 (1 lmol/L) or its combination with IBC (8 lmol/L) for 72 h and subsequently treated with paclitaxel
(5 nmol/L) for 14 d before being subjected to colony formation assay. *P < .05, **P < .01
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paclitaxel-sensitive cells transfected with ERa (Fig. 3C). Moreover,
the viability of ZR-75-1 and MCF-7 cells transfected with ERa was
higher than that of cells transfected with control plasmids (Figure 3D
and E). Interestingly, IBC could clearly reverse the increase in expres-
sion of ERa and CD44 stimulated by E2 as shown by real-time PCR
and Western blotting (Figure 3F and G). Taken together, these
results suggested that IBC could decrease CD44 expression in an
ERa-dependent manner.
3.4 | Establishment of paclitaxel-resistant ZR-75-1/
R and MCF-7/R cell lines
To study the roles of ERa and CD44 in the acquisition of resistance
to anticancer agents, we selected ERa+ breast cancer cells to estab-
lish drug-resistant cell models. As mentioned in Materials and Meth-
ods, paclitaxel-sensitive ZR-75-1 and MCF-7 cells were first treated
with 2.5 nmol/L paclitaxel. When ZR-75-1 and MCF-7 cells survived
at any given concentration of the drug, the cells were passaged at
another concentration that was 1.5- to twofold higher. After step-
wise selection with increasing paclitaxel concentrations, we obtained
ZR-75-1/R and MCF-7/R cells, which were able to survive in
50 nmol/L paclitaxel (Figure 4A). Then, cytotoxicity assays were car-
ried out in ZR-75-1/R and MCF-7/R cells to characterize resistance
phenotypes. The results demonstrated that the viability of paclitaxel-
resistant cells was higher than that of paclitaxel-sensitive cells (Fig-
ure 4B and C). Furthermore, the IC50 values of ZR-75-1 and ZR-75-
1/R cells were 191.3  21.78 and 5151.64  631.08, respectively,
whereas the IC50 values of MCF-7 and MCF-7/R cells were
188.71  15.96 and 3147.44  469.1, respectively (Figure 4D). The
RI of the established ZR-75-1/R and MCF-7/R cells was 26.9 and
16.8, respectively, and this result sufficiently demonstrated that
those two cell lines were resistant to paclitaxel. It is known that high
expression of multidrug resistance protein P-gp makes cancer cells
tolerant to chemotherapeutic drugs.31,32 Therefore, we detected
F IGURE 2 E2 could stimulate CD44 expression in ER+ breast cancer cells. A, CD44 transcript level was detected by real-time PCR in ER+
ZR-75-1 cells treated with the indicated concentrations of E2 for 72 h. B, CD44 transcript level was detected by real-time PCR in ER+ MCF-7
cells treated with the indicated concentrations of E2 for 72 h. C, CD44 transcript level was detected by real-time PCR in ER- MDA-MB-231
cells treated with the indicated concentrations of E2 for 72 h. D, Real-time PCR analysis of CD24 expression in ER+ ZR-75-1 cells treated with
the indicated concentrations of E2 for 72 h. E, Real-time PCR analysis of CD24 expression in ER+ MCF-7 cells treated with the indicated
concentrations of E2 for 72 h. F, Real-time PCR analysis of CD24 expression in ER+ MCF-7 cells treated with the indicated concentrations of
E2 for 72 h. G, Western blot analysis of CD44 protein expression in breast cancer cells treated with E2 (1 lmol/L) for 72 h. H, Western blot
analysis of CD44 protein expression in ER+ MCF-7 cells transfected with CD44-targeting siRNA. H, Western blot analysis of CD44 protein
expression in ER+ MCF-7 cells transfected with CD44-targeting siRNA. I, MCF-7 cells described in Figure 1 were treated with paclitaxel
(5 nmol/L) for 14 d before being subjected to colony formation assay. *P < .05, **P < .01
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P-gp expression in the paclitaxel-resistant cell models. Compared
with that in paclitaxel-sensitive cells, the expression level of P-gp
was significantly increased in paclitaxel-resistant cells (Figure 4E),
which indicated that ZR-75-1/R and MCF-7/R cells were chemother-
apeutic drug-resistant breast cancer cells. Interestingly, compared
with those in paclitaxel-sensitive cells, the expression levels of ERa
and CD44 were also increased in paclitaxel-resistant cells (Figure 4E
and F), suggesting that ERa and CD44 are up-regulated by paclitaxel
and might be involved in the acquisition of the drug resistance phe-
notype in ERa+ breast cancer cells. This was consistent with our pre-
vious findings and strongly suggested that ERa expression was
significantly positively correlated with CD44 expression in paclitaxel-
resistant breast cancer cells.
3.5 | Knockdown of ERa significantly decreased
CD44 gene expression to render breast cancer cells
sensitive to paclitaxel
To evaluate the function of IBC in the paclitaxel resistance pheno-
types of ERa+ breast cancer cells, we detected the protein expres-
sion of ERa and CD44 in paclitaxel-resistant breast cancer cells
with IBC treatment. Indeed, compared with that in control cells,
the expression of ERa and CD44 protein was down-regulated in
paclitaxel-resistant cells treated with IBC (Figure 5A). Paclitaxel
blocks the G2/M phase of cell cycle and induces cancer cell
apoptosis.33 As shown in Figure 5B and C, IBC could increase the
proportion of cells in G2/M phase as determined by flow
F IGURE 3 ERa could enhance CD44 expression to promote the resistance of ER+ breast cancer cells to paclitaxel. A, Western blot analysis
of ERa protein expression in ER+ breast cancer cells treated with E2 (1 lmol/L). B, Western blot analysis of ERa protein expression in ZR-75-1
and MCF-7 cells transfected with empty vector or ERa expression plasmids. C, Real-time PCR analysis of CD44 expression in ZR-75-1 and
MCF-7 cells transfected with vector or ERa expression plasmids. D, ZR-75-1 cells were treated with the indicated concentrations of paclitaxel
for 72 h and subjected to cell viability assay. E, MCF-7 cells were treated with the indicated concentrations of paclitaxel for 72 h and
subjected to cell viability assay. F, Real-time PCR analysis of CD44 transcript expression in both ZR-75-1 and MCF-7 cells treated with E2
(100 nmol/L) or its combination with IBC (8 lmol/L) for 72 h. G, Western blot analysis of ERa and CD44 protein expression in MCF-7 and
MCF-7/R cells treated with E2 (1 lmol/L) or its combination with IBC (8 lmol/L) for 72 h. *P < .05, **P < .01
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cytometry in MCF-7/R cells treated with paclitaxel. These results
indicated that IBC sensitized cells to paclitaxel to some extent by
blocking cell cycle progression in ER+ breast cancer cells. To fur-
ther confirm whether IBC reduced the expression of CD44 by
regulating the ERa pathway, we carried out the ERa interference
experiment in paclitaxel-resistant breast cancer cells. The effi-
ciency of ERa knockdown by ERa-shRNA was confirmed by Wes-
tern blotting (Figure 5D). Real-time PCR showed that compared
with that in cells transfected with control plasmids, the expres-
sion of CD44 mRNA was down-regulated in paclitaxel-resistant
cells transfected with ERa-shRNA (Figure 5E). In addition, knock-
down of ERa expression with ERa-shRNA significantly decreased
the number of viable ZR-75-1/R and MCF-7/R cells (Figure 5F
and G), indicating that IBC could down-regulate CD44 expression
by the ERa pathway to sensitize of resistant breast cancer cells
to paclitaxel.
3.6 | IBC antagonized tumour growth by reducing
ERa and CD44 expression in a paclitaxel-resistant
mouse xenograft model
To evaluate the clinical implications of our findings, we also studied
the functional effect of IBC in vivo in established paclitaxel-resistant
breast cancer xenograft models. Treatment with IBC reduced tumour
growth in the mouse xenograft model (Figure 6A). In addition, the
levels of ERa and CD44 were lower in the IBC group than in the
control group by immunohistochemical (IHC) staining and IPP soft-
ware analysis (Figure 6B and C), and a positive correlation was
observed between ERa and CD44 in MCF-7/R mouse xenograft
tumours treated with IBC. These results suggested that IBC dis-
played an antitumour activity in MCF-7/R xenograft tumour models.
4 | DISCUSSION
Drug resistance is one of the major obstacles limiting the success of
cancer chemotherapy. In recent years, both clinical observations and
experimental studies have shown that the therapeutic efficacy of
anticancer drugs can be altered by steroid hormones and their recep-
tors, but the potential molecular mechanisms remain unclear.34-36 In
this study, using our established paclitaxel-resistant breast cancer
cells, we explored whether and how IBC influenced paclitaxel resis-
tance in breast cancer cells via the ERa-dependent pathway. First,
we verified that IBC can reverse E2-induced paclitaxel resistance in
ER+ breast cancer cells. Furthermore, we confirmed a positive corre-
lation between the expression level of ERa and CD44 in our
F IGURE 4 The expression of ERa and CD44 increased simultaneously in paclitaxel-resistant ER+ breast cancer cells we established. A,
Morphology of paclitaxel-resistant ZR-75-1/R and MCF-7/R cells. B, Number of viable paclitaxel-resistant ZR-75-1/R cells and their parental
cells treated with the indicated concentrations of paclitaxel for 72 h as determined by cell viability assay. C, Number of viable paclitaxel-
resistant MCF-7/R cells and their parental cells treated with the indicated concentrations of paclitaxel for 72 h as determined by cell viability
assay. D, IC50 values were calculated in paclitaxel-resistant cells and their parental cells from B and C. E, Western blot analysis of P-gp and
ERa protein expression in paclitaxel-resistant cells and their parental cells. F, Real-time PCR analysis of CD44 transcript level in paclitaxel-
resistant cells and their parental cells. *P < .05, **P < .01
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F IGURE 5 Knockdown of ERa significantly decreased CD44 gene expression to sensitize breast cancer cells to paclitaxel. A, Western blot
analysis of ERa and CD44 protein expression in MCF-7/R cells treated IBC (8 lmol/L) for 72 h. B, MCF-7/R cells were pretreated with control
or IBC (8 lmol/L) for 72 h and subsequently treated with 100 nmol/L paclitaxel for 6 h and subjected to flow cytometry for the analysis of
cell cycle distribution. C, Quantitative analysis of the percentage of cells in G2/M phase from three independent experiments is shown. D,
Western blot analysis of ERa protein expression in paclitaxel-resistant ZR-75-1/R and MCF-7/R cells transfected with empty vector or ERa
knockdown plasmids. E, Real-time PCR analysis of CD44 expression in ZR-75-1/R and MCF-7/R cells transfected with empty vector or ERa
knockdown plasmids. F, ZR-75-1/R cells were treated with the indicated concentrations of paclitaxel for 72 h and subjected to cell viability
assay. G, MCF-7/R cells were treated with the indicated concentrations of paclitaxel for 72 h and subjected to cell viability assay. *P < .05,
**P < .01
F IGURE 6 IBC down-regulated CD44 expression mediated by the ERa pathway and inhibited tumour growth in MCF-7/R xenograft
models. A, MCF-7/R cells were subcutaneously injected into the right flank of nude mice (6 mice per group) on day 0. When the tumour
volume reached 50 mm3, the mice were intraperitoneally administered with IBC (100 mg/kg) daily for 24 d. Tumour volume was measured at
the indicated time-points. B, Representative immunohistochemistry images of ERa and CD44 staining in tumour tissues of nude mice. C,
Quantitative image analysis utilized IPP software on immunohistochemical staining described in Figure 6B of ERa and CD44 protein
expression. *P < .05, **P < .01
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established paclitaxel-resistant ER+ breast cancer cells. Moreover,
knockdown of ERa expression by shRNA or IBC increased the sensi-
tivity of cells with a decreased expression of CD44 to paclitaxel.
Finally, using xenograft tumour models, we confirmed that IBC could
reduce tumour growth in ER+ xenografts by inhibiting ERa and
CD44 expression.
De novo anti-oestrogen resistance is observed mainly in ER-/PR-
tumours, but cancer cells can sometimes switch the phenotype from
ER+ to ER.37,38 Based on failure to endocrine therapy, the patients
can be treated with chemical therapeutic agents. Paclitaxel, a first-
line clinical chemotherapy drug, is used in the treatment of various
human solid tumours, including breast cancer.39,40 However, some
types of breast tumours are resistant to paclitaxel. Cumulative data
from clinical studies and retrospective studies indicate that the ER
status might affect the therapeutic efficacy of paclitaxel because
paclitaxel is less effective in patients with ER+ breast tumours than
in patients with ER- breast tumours.5,41 However, most of these
data were obtained from comparative studies in tumour cell lines
extracted from different patients. Thus, it is difficult to reach a con-
sensus on cellular and molecular mechanisms in these cell lines.
Therefore, the comparison of established paclitaxel-resistant breast
cell lines and parental breast cell lines may provide us with a valu-
able model system to explore the mechanism underlying ERa-
mediated resistance to paclitaxel and other chemotherapeutic agents
in breast tumour cells.
IBC is a traditional Chinese medicine that has been used as an
antibacterial and antitumour agent. Recent studies support the
notion that IBC can inhibit human tongue and liver cancer cells by
blocking the Akt signalling pathway.21 However, we observed no
connection between IBC treatment and drug-resistant breast cancer
cells. It is obvious that the relationship between IBC and drug resis-
tance needs to be further elucidated in greater detail. Our results
have shown that IBC could down-regulate the expression of ERa
and CD44, leading to cellular sensitivity to paclitaxel. However, it is
worth investigating whether IBC can be used to treat other drug-
resistant cancer cells. It is well-known that E2 can promote the pro-
liferation of breast cancer cells. This study indicated that E2 could
active ERa expression to promote drug resistance in ER+ breast can-
cer. However, the effect of IBC as a phytoestrogen on ERa is not
clear. Our work further demonstrated that IBC could down-regulate
ERa expression to prevent ERa-related resistance of tumour cells. In
this regard, the present study provided a potential antitumour mech-
anism of IBC.
In this study, for the first time, we correlated ERa and CD44
expression, revealing a potential mechanism that ERa could enhance
paclitaxel resistance in ER+ breast cancer cells by up-regulating
CD44 expression. In our study, we proposed the following drug
resistance model: during paclitaxel therapy for breast cancer, pacli-
taxel can active ERa expression and then ERa can transcriptionally
regulate the CD44 gene, which is responsible for resistance to
chemotherapy agents. Therefore, ERa can be developed as a thera-
peutic target in the context of CD44 activation to overcome drug
resistance in the clinic.
CD44 is closely associated with chemotherapeutic drug resistance
in cancer cells. Previous studies have revealed that CD44 is highly
expressed in triple-negative breast cancer (TNBC) and correlated with
poor survival of TNBC patients.42 Of note, CD44 also plays a key role
in ER+ breast cancer, resulting in poor prognosis and radiotherapy
resistance.42 However, the role of CD44 in drug resistance of ER+
breast cancer is worth studying in depth. Interestingly, in this study, a
high expression of CD44 was positively correlated with ERa existed
in our established paclitaxel-resistant ER+ breast cancer cells. It is
worth investigating whether the high expression of CD44 increased
the resistance of cells. The present study proved that the high expres-
sion of CD44 mediated by E2-ERa is an important factor rendering
cells resistant to paclitaxel. This is in agreement with the notion that
IBC down-regulates CD44 expression by the ERa pathway to sensitize
breast cancer cells to paclitaxel. In conclusion, the present study pro-
vided a potential antitumour mechanism of IBC.
In summary, the present study demonstrated that the ER status
might play a significant role in determining the sensitivity of breast
cancer to paclitaxel. The results obtained from this study may pro-
vide valuable information for improving the understanding of CD44-
mediated resistance to paclitaxel and the clinical application of this
class of antineoplastic drugs. Further studies are necessary to eluci-
date the resistance phenotype by which CD44 expression is regu-
lated by ERa in other hormone-dependent tumours. These studies
will help provide a new possibility for the clinical treatment of cancer
in premenopausal women.
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